<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Thyrotoxic periodic paralysis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Thyrotoxic periodic paralysis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Thyrotoxic periodic paralysis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Laurie Gutmann, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robin Conwit, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jeremy M Shefner, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Janet L Wilterdink, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jun 13, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Periodic paralysis (PP) is a muscle disease in the family of diseases called channelopathies, manifested by episodes of painless muscle weakness. These episodes may be precipitated by heavy exercise, fasting, or high-carbohydrate meals. PP is classified as hypokalemic when episodes occur in association with low potassium blood levels or as hyperkalemic when episodes can be induced by elevated potassium. Most cases of PP are hereditary, usually with an autosomal dominant inheritance pattern. Acquired cases of hypokalemic PP have been described in association with hyperthyroidism. The clinical features of these disorders are summarized in the table (
         <a class="graphic graphic_table graphicRef65215" href="/z/d/graphic/65215.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
         In contrast to other forms of thyroid disease, which are more common in females, thyrotoxic PP is much more frequently seen in males; the prevalence of thyrotoxic PP is also highest in East Asian populations [
         <a href="#rid1">
          1,2
         </a>
         ]. This diagnosis should be considered when this demographic of patients presents with marked painless weakness after provocation with exercise or changes in diet [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         Thyrotoxic PP will be reviewed here. Other causes of PP and other neurologic manifestations of thyrotoxicosis are discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5150.html" rel="external">
          "Hypokalemic periodic paralysis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5152.html" rel="external">
          "Hyperkalemic periodic paralysis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4836.html" rel="external">
          "Neurologic manifestations of hyperthyroidism and Graves' disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Thyrotoxic PP is a sporadic form of hypokalemic PP that may occur in association with hyperthyroidism. This contrasts with familial hypokalemic PP, which has an autosomal dominant inheritance [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         Any etiology of hyperthyroidism, including thyroxine abuse, can be associated with thyrotoxic PP [
         <a href="#rid4">
          4-8
         </a>
         ]. Graves' disease is the underlying disorder in most cases of thyrotoxic PP, as it is in most cases of hyperthyroidism [
         <a href="#rid8">
          8-11
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7871.html" rel="external">
          "Disorders that cause hyperthyroidism"
         </a>
         .)
        </p>
        <p>
         Thyrotoxic PP has been most widely reported and studied in East Asian populations, in which the incidence among patients with hyperthyroidism is approximately 2 percent [
         <a href="#rid12">
          12,13
         </a>
         ]. This contrasts with other populations, in which the incidence of thyrotoxic PP among individuals with hyperthyroidism is estimated to be 0.1 to 0.2 percent. A New Zealand study found that Polynesians were also at higher risk for thyrotoxic PP compared with those of European descent [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
         Despite a higher incidence of hyperthyroidism in females, over 95 percent of thyrotoxic PP cases occur in males [
         <a href="#rid11">
          11,15,16
         </a>
         ]. Thus, the incidence of thyrotoxic PP is particularly high among East Asian males with thyrotoxicosis (8.7 to 13 percent) [
         <a href="#rid17">
          17,18
         </a>
         ].
        </p>
        <p>
         The age of onset of symptoms in thyrotoxic PP is between 20 and 39 years in approximately 80 percent of patients [
         <a href="#rid11">
          11,12,16,17,19-22
         </a>
         ]. Although this later age of onset is helpful to distinguish thyrotoxic PP from the familial PPs, which present at a younger age, adolescents with thyrotoxic PP have been reported [
         <a href="#rid23">
          23,24
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The mechanism by which hyperthyroidism can produce hypokalemic PP is not well understood. Thyroid hormone increases tissue responsiveness to beta-adrenergic stimulation, which, along with thyroid hormone, increases sodium-potassium ATPase activity on the skeletal muscle membrane [
         <a href="#rid19">
          19
         </a>
         ]. This tends to drive potassium into cells, perhaps leading to hyperpolarization of the muscle membrane and relative inexcitability of the muscle fibers. Thyrotoxic patients with PP have been found to have higher sodium pump activity than those without paralytic episodes [
         <a href="#rid5">
          5,25
         </a>
         ]. In this way, excess thyroid hormone may predispose to paralytic episodes by increasing the susceptibility to the hypokalemic action of
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          epinephrine
         </a>
         or insulin [
         <a href="#rid12">
          12,26
         </a>
         ].
        </p>
        <p>
         Insulin resistance with compensatory hyperinsulinemia is suspected to have a role in the pathogenesis of thyrotoxic PP [
         <a href="#rid27">
          27,28
         </a>
         ]. In one study, patients with a history of thyrotoxic PP were heavier and exhibited reduced insulin sensitivity compared with patients with thyrotoxicosis without thyrotoxic PP. Insulin also activates the sodium-potassium ATPase pump and may act synergistically with thyroid hormone to drive potassium into cells. This is consistent with the observation that a heavy meal can be a precipitant for attacks of thyrotoxic PP.
        </p>
        <p>
         While patients with thyrotoxic PP do not have the genetic mutations associated with familial hypokalemic PP, it has been suggested that individuals who are susceptible to thyrotoxic PP may have an ion channel defect, which, in the euthyroid state, is not sufficient to produce symptoms [
         <a href="#rid9">
          9,23,29-33
         </a>
         ]. A number of studies have identified specific susceptibility loci that confer risk for thyrotoxic PP. Many but not all of these affect
         <em>
          KCNJ2
         </em>
         expression; this gene encodes Kir2.6, an inwardly rectifying potassium channel, expressed in skeletal muscle that is transcriptionally regulated by thyroid hormone [
         <a href="#rid34">
          34-39
         </a>
         ]. Some but not all of these loci have been implicated in Graves' disease [
         <a href="#rid36">
          36
         </a>
         ]. The frequency of these genes varies in different ethnic populations, which is thought to explain the higher prevalence of thyrotoxic PP in these populations.
        </p>
        <p>
         A role for testosterone in the pathogenesis for thyrotoxic PP is suggested by the predominance of this condition in men and the demonstration that testosterone increases sodium-potassium ATPase activity in animals [
         <a href="#rid40">
          40-42
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          CLINICAL FEATURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         As with all the PPs, attacks of weakness occur suddenly with generalized weakness and preserved consciousness.
        </p>
        <p>
         In many patients, clinical features of hyperthyroidism precede the onset of PP by months or even years, but they have been noted to occur at the same time (in 43 to 60 percent of patients) or following the development of PP (in 11 to 17 percent) [
         <a href="#rid12">
          12,15,18,19,21,22,43,44
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7833.html" rel="external">
          "Overview of the clinical manifestations of hyperthyroidism in adults"
         </a>
         .)
        </p>
        <p>
         Neurologic examination during an attack demonstrates weakness, usually affecting proximal more than distal muscles, and the legs more than the arms [
         <a href="#rid5">
          5,16,20,21,45
         </a>
         ]. Mild myalgia is a complaint in less than half of patients [
         <a href="#rid16">
          16
         </a>
         ]. Decreased muscle tone with hyporeflexia or areflexia is typical, although normal or hyperactive reflexes may be observed. In one series, tachycardia (mean heart rate = 105 bpm) was noted at presentation and distinguished these patients from those with familial hypokalemic PP [
         <a href="#rid43">
          43
         </a>
         ]. Exceptional cases of bulbar weakness and respiratory weakness requiring ventilatory support have been reported in thyrotoxic PP, as well as cases of severe, even fatal, arrhythmias (sinus arrest, second degree atrioventricular [AV] block, ventricular fibrillation, and ventricular tachycardia) [
         <a href="#rid8">
          8,46-49
         </a>
         ].
        </p>
        <p>
         Attacks vary in frequency and duration, as well as their association with inciting events:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intervals of weeks to months are common, but some patients experience several attacks per week [
         <a href="#rid16">
          16,45
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A duration of symptoms of several hours is typical, but can range from minutes to days.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         As with hypokalemic PP, attacks in thyrotoxic PP can be precipitated by events that are associated with an increased release of
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          epinephrine
         </a>
         or insulin, both of which cause movement of potassium into cells and low potassium blood levels [
         <a href="#rid16">
          16,29
         </a>
         ]. Most commonly, the inciting event is either rest after strenuous physical activity, stress, or a high-carbohydrate load [
         <a href="#rid11">
          11
         </a>
         ]. Other events reported to induce attacks in thyrotoxic PP include cold exposure, infection, alcohol intake, pulse corticosteroid therapy, beta-2 adrenergic bronchodilator use, and menses [
         <a href="#rid12">
          12,22,50-54
         </a>
         ]. Administration of epinephrine, insulin, or thyroid supplements may also precipitate attacks. In many instances, no obvious precipitant is identified [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Although attacks of weakness may occur at any time of the day, a high frequency of attacks at night or early in the morning has been reported in thyrotoxic PP [
         <a href="#rid8">
          8
         </a>
         ]. A seasonal variation has also been suggested, with more frequent attacks in summer months [
         <a href="#rid11">
          11,18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          LABORATORY FEATURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         The degree of hypokalemia during an attack is variable; in one series of 78 patients the mean serum potassium level was 2.1 mmol/L [
         <a href="#rid20">
          20
         </a>
         ]. Cases with extremely low potassium levels &lt;1.5 mEq/L are frequently reported [
         <a href="#rid5">
          5,8,16,21,46-48,55
         </a>
         ]. However, in at least two cases of PP attributed to thyrotoxic PP, the ictal potassium level was normal [
         <a href="#rid16">
          16,56,57
         </a>
         ]. Usually, the severity of weakness corresponds to the degree of hypokalemia [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
         Patients with thyrotoxic PP, by definition, have attacks in the hyperthyroid state. Supporting laboratory findings include elevation of serum thyroxine (T4) and low thyrotropin levels (TSH). Patients with elevated T3 and normal T4 levels have been reported [
         <a href="#rid11">
          11,58
         </a>
         ].
        </p>
        <p>
         Other common laboratory findings include mild hypophosphatemia and hypomagnesemia [
         <a href="#rid8">
          8,21,22
         </a>
         ]. These findings may help distinguish thyrotoxic PP from familial hypokalemic PP [
         <a href="#rid43">
          43,45,59
         </a>
         ]. In one study, a urine calcium to phosphate ratio of higher than 1.7 was a sensitive and specific test to distinguish thyrotoxic PP from familial hypokalemic PP [
         <a href="#rid60">
          60
         </a>
         ]. Creatine kinase may be normal but has been reported to be mildly elevated in two-thirds of patients, and rhabdomyolysis has been reported [
         <a href="#rid8">
          8,61
         </a>
         ]. In one case series, hypocreatininemia (0.6 ± 0.15 mg/dL) and a high estimated glomerular filtration rate (eGFR; 168.1 ± 37.8 mL/minute per 1.73 m
         <sup>
          2
         </sup>
         ) were noted [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
         Electrocardiogram (ECG) changes are common in an attack of thyrotoxic PP. These include those findings consistent with hypokalemia: ST depression, sinus tachycardia, U waves (
         <a class="graphic graphic_waveform graphicRef73888" href="/z/d/graphic/73888.html" rel="external">
          waveform 1
         </a>
         ), as well as those not consistently associated with hypokalemia: an elevated higher heart rate, abnormal PR interval, higher QRS voltage, and first-degree atrioventricular (AV) block [
         <a href="#rid55">
          55,62
         </a>
         ]. The latter category of ECG findings is more common in patients with thyrotoxic PP as compared with patients with familial hypokalemic PP [
         <a href="#rid59">
          59
         </a>
         ]. Severe arrhythmias (eg, sinus arrest, second-degree AV block, ventricular fibrillation, and ventricular tachycardia) are not common but are described [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          DIAGNOSIS AND DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         In an acute attack, thyrotoxic PP must be distinguished from other causes of acute quadriparesis, such as myasthenic crisis, Guillain-Barré syndrome, acute myelopathy (eg, transverse myelitis), acute thyrotoxic myopathy, tick paralysis, and botulism [
         <a href="#rid4">
          4,8,64
         </a>
         ]. Other forms of PP are also considered (
         <a class="graphic graphic_table graphicRef65215" href="/z/d/graphic/65215.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
         The finding of hypokalemia and recovery with treatment generally alerts the clinician to the diagnosis of hypokalemic PP, in which the possibility of thyrotoxicosis must always be evaluated, particularly in the absence of a family history of PP. (See
         <a class="medical medical_review" href="/z/d/html/5150.html" rel="external">
          "Hypokalemic periodic paralysis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7847.html" rel="external">
          "Diagnosis of hyperthyroidism"
         </a>
         .)
        </p>
        <p>
         After a thyrotoxic state is established, the patient is further evaluated to determine the underlying cause. (See
         <a class="medical medical_review" href="/z/d/html/7871.html" rel="external">
          "Disorders that cause hyperthyroidism"
         </a>
         .)
        </p>
        <p>
         The results of electromyography, provocative testing, and muscle biopsy are similar to those seen in familial hypokalemic PP, but these tests are often unnecessary. (See
         <a class="medical medical_review" href="/z/d/html/5150.html" rel="external">
          "Hypokalemic periodic paralysis", section on 'Diagnostic evaluation'
         </a>
         .)
        </p>
        <p>
         If thyrotoxicosis is not established as the cause, an ECG should be performed to identify a prolonged QT or QU interval suggestive of Andersen syndrome (
         <a class="graphic graphic_waveform graphicRef77018" href="/z/d/graphic/77018.html" rel="external">
          waveform 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/5150.html" rel="external">
          "Hypokalemic periodic paralysis", section on 'Andersen syndrome'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          ACUTE TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with acute paralysis are typically hospitalized in a monitored setting for cardiac arrhythmias as well as dysphagia.
        </p>
        <p class="headingAnchor" id="H1570150672">
         <span class="h2">
          Potassium supplementation
         </span>
         <span class="headingEndMark">
          —
         </span>
         A suggested protocol is 30 mEq of oral potassium every two hours until improvement begins, with a maximum dose of 90 mEq in 24 hours [
         <a href="#rid65">
          65
         </a>
         ]. Some recommend slower rates of administration (&lt;10 mEq per hour) [
         <a href="#rid5">
          5,66
         </a>
         ]. Intravenous supplementation may be necessary for patients with severe hypokalemia or impaired swallowing. (See
         <a class="medical medical_review" href="/z/d/html/2297.html" rel="external">
          "Clinical manifestations and treatment of hypokalemia in adults", section on 'Intravenous potassium repletion'
         </a>
         .)
        </p>
        <p>
         As with familial hypokalemic PP, potassium supplementation may lead to improvement of weakness. One prospective study compared treatment with intravenous
         <a class="drug drug_general" data-topicid="9795" href="/z/d/drug information/9795.html" rel="external">
          potassium chloride
         </a>
         to normal
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         infusion and found a shorter recovery time with use of potassium (6.3 versus 13.5 hours) [
         <a href="#rid66">
          66
         </a>
         ]. In a retrospective case series, patients who received intravenous potassium recovered more quickly than those who received oral supplementation [
         <a href="#rid57">
          57
         </a>
         ]. There may be a delayed response of a few hours following potassium administration [
         <a href="#rid48">
          48
         </a>
         ]. Required doses of potassium supplementation are variable and range from 10 to 200 mEq [
         <a href="#rid5">
          5,8,20
         </a>
         ].
        </p>
        <p>
         Rebound hyperkalemia appears to be a prominent problem in thyrotoxic PP, occurring in approximately 40 to 59 percent of treated attacks [
         <a href="#rid8">
          8,20,21
         </a>
         ]. In one study, 80 percent of patients who developed rebound hyperkalemia had received greater than 90 mEq of potassium within 24 hours. In one case series, a fall in serum potassium occurred during initial treatment in one-fourth of patients; these patients also had higher free thyroxine levels, ultimately required higher doses of potassium supplementation, and were more likely to have severe rebound hyperkalemia [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3671274187">
         <span class="h2">
          Monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         Close monitoring of serum potassium during the acute paralysis is essential.
        </p>
        <p>
         Continuous cardiac monitoring is recommended for all patients during treatment and observation. A cardiology consultation should be obtained for severe arrhythmias/ECG changes. Correction of hypomagnesemia, if present, is also recommended.
        </p>
        <p class="headingAnchor" id="H1586966231">
         <span class="h2">
          Refractory patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         Replacement of potassium may be insufficient to resolve an attack. Intravenous
         <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">
          propranolol
         </a>
         has been reported to reverse weakness and hypokalemia in patients with thyrotoxic PP that is unresponsive to potassium administration [
         <a href="#rid48">
          48,50,67,68
         </a>
         ]. These patients received doses of 1 mg of intravenous propranolol every 10 minutes up to a maximum dose of 3 mg. In one report, oral propranolol, 3 mg/kg, administered without potassium supplementation reversed both weakness and hypokalemia in two patients with an acute attack of thyrotoxic PP without inducing rebound hyperkalemia [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">
          Propranolol
         </a>
         , a beta adrenergic blocker, presumably reverses the excessive stimulation of the sodium-potassium ATPase and excessive drive of potassium into cells. (See
         <a class="local">
          'Pathogenesis'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          PREVENTIVE TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Restoration of euthyroidism eliminates attacks of thyrotoxic PP [
         <a href="#rid11">
          11,12,69
         </a>
         ]. When patients become euthyroid, the electromyography (EMG) exercise test normalizes, and attacks are no longer inducible [
         <a href="#rid70">
          70
         </a>
         ]. Thyrotoxic PP can reemerge if thyrotoxicosis recurs. The management of hyperthyroidism differs according to the underlying etiology. In a series of 16 patients with thyrotoxic PP secondary to Graves' disease who were followed for 14 years, treatment with radioactive iodine or surgery appeared to be more effective in preventing relapses than treatment with antithyroid drugs alone [
         <a href="#rid71">
          71
         </a>
         ].
        </p>
        <p>
         The administration of beta-blocking medications such as
         <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">
          propranolol
         </a>
         , 40 to 120 mg daily, with or without potassium supplementation appears to decrease the frequency and severity of attacks, and may be used as a temporizing measure until a euthyroid state is achieved [
         <a href="#rid19">
          19,26,58,67,72,73
         </a>
         ]. A nonselective beta blocker (eg, propranolol) should be given; beta-1 selective agents are less likely to inhibit the beta-2 receptor-mediated hypokalemic effect of
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          epinephrine
         </a>
         and may therefore be less likely to prevent paralytic episodes [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
         In contrast to familial hypokalemic PP, carbonic anhydrase inhibitors have not been shown to be of benefit in thyrotoxic PP and may even increase the frequency of attacks [
         <a href="#rid74">
          74
         </a>
         ]. Potassium supplementation is not effective as prophylaxis in thyrotoxic PP [
         <a href="#rid9">
          9
         </a>
         ]. As with hypokalemic PP, precipitating factors, such as heavy exercise, high-carbohydrate diets, and alcohol, should be avoided.
        </p>
        <p class="headingAnchor" id="H21676790">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/83672.html" rel="external">
          "Patient education: Periodic paralysis syndrome (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology and pathogenesis
         </strong>
         – Thyrotoxic periodic paralysis (PP) represents an acquired form of hypokalemic PP. Any cause of hyperthyroidism can be associated with thyrotoxic PP. (See
         <a class="local">
          'Pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Thyrotoxic PP is more prevalent in East Asian compared with other populations and also in males compared with females. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical and laboratory features
         </strong>
         – Attacks of generalized weakness are often precipitated by rest after strenuous exercise or a high carbohydrate load. Potassium levels are often very low but are sometimes normal. (See
         <a class="local">
          'Clinical features'
         </a>
         above and
         <a class="local">
          'Laboratory features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis of thyrotoxic PP is made when a patient presents with a paralytic attack that is associated with hypokalemia and hyperthyroidism. The distinguishing clinical features of hypokalemic, thyrotoxic, and hyperkalemic PP, and the Andersen syndrome, are summarized in the table (
         <a class="graphic graphic_table graphicRef65215" href="/z/d/graphic/65215.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Diagnosis and differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acute treatment
         </strong>
         – For treatment of an acute attack of thyrotoxic PP with severe weakness, we recommend administration of
         <a class="drug drug_general" data-topicid="9795" href="/z/d/drug information/9795.html" rel="external">
          potassium chloride
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). Patients should be on cardiac monitoring, and potassium levels should be monitored for potential rebound hyperkalemia for 24 hours. A suggested protocol is potassium 30 mEq every two hours, with a maximum dose of 90 mEq in 24 hours. Oral administration, if possible, is preferred. (See
         <a class="local">
          'Acute treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For acute weakness, which is not responding to potassium administration, we suggest using
         <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">
          propranolol
         </a>
         , 1 mg intravenously or 3 mg/kg orally (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Acute treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Preventive and long-term management
         </strong>
         – Attacks of PP will cease with return to euthyroid state. Interim measures to ameliorate attacks include avoiding strenuous exercise and high-carbohydrate loads. If attacks continue to be problematic, we recommend prophylactic use of
         <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">
          propranolol
         </a>
         until euthyroidism is achieved (
         <a class="grade" href="https:///uptodate/show/grade_3" rel="external">
          Grade 1C
         </a>
         ). (See
         <a class="local">
          'Preventive treatment'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Vijayakumar A, Ashwath G, Thimmappa D. Thyrotoxic periodic paralysis: clinical challenges. J Thyroid Res 2014; 2014:649502.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chaudhry MA, Wayangankar S. Thyrotoxic Periodic Paralysis: A Concise Review of the Literature. Curr Rheumatol Rev 2016; 12:190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel H, Wilches LV, Guerrero J. Thyrotoxic periodic paralysis: diversity in America. J Emerg Med 2014; 46:760.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen YC, Fang JT, Chang CT, Chou HH. Thyrotoxic periodic paralysis in a patient abusing thyroxine for weight reduction. Ren Fail 2001; 23:139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pompeo A, Nepa A, Maddestra M, et al. Thyrotoxic hypokalemic periodic paralysis: An overlooked pathology in western countries. Eur J Intern Med 2007; 18:380.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hannon MJ, Behan LA, Agha A. Thyrotoxic periodic paralysis due to excessive L-thyroxine replacement in a Caucasian man. Ann Clin Biochem 2009; 46:423.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chou HK, Tsao YT, Lin SH. An unusual cause of thyrotoxic periodic paralysis: triiodothyronine-containing weight reducing agents. Am J Med Sci 2009; 337:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manoukian MA, Foote JA, Crapo LM. Clinical and metabolic features of thyrotoxic periodic paralysis in 24 episodes. Arch Intern Med 1999; 159:601.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kung AW. Clinical review: Thyrotoxic periodic paralysis: a diagnostic challenge. J Clin Endocrinol Metab 2006; 91:2490.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pothiwala P, Levine SN. Analytic review: thyrotoxic periodic paralysis: a review. J Intensive Care Med 2010; 25:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang CC, Cheng CJ, Sung CC, et al. A 10-year analysis of thyrotoxic periodic paralysis in 135 patients: focus on symptomatology and precipitants. Eur J Endocrinol 2013; 169:529.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ober KP. Thyrotoxic periodic paralysis in the United States. Report of 7 cases and review of the literature. Medicine (Baltimore) 1992; 71:109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kelley DE, Gharib H, Kennedy FP, et al. Thyrotoxic periodic paralysis. Report of 10 cases and review of electromyographic findings. Arch Intern Med 1989; 149:2597.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elston MS, Orr-Walker BJ, Dissanayake AM, Conaglen JV. Thyrotoxic, hypokalaemic periodic paralysis: Polynesians, an ethnic group at risk. Intern Med J 2007; 37:303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ko GT, Chow CC, Yeung VT, et al. Thyrotoxic periodic paralysis in a Chinese population. QJM 1996; 89:463.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hsieh MJ, Lyu RK, Chang WN, et al. Hypokalemic thyrotoxic periodic paralysis: clinical characteristics and predictors of recurrent paralytic attacks. Eur J Neurol 2008; 15:559.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           OKINAKA S, SHIZUME K, IINO S, et al. The association of periodic paralysis and hyperthyroidism in Japan. J Clin Endocrinol Metab 1957; 17:1454.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McFadzean AJ, Yeung R. Periodic paralysis complicating thyrotoxicosis in Chinese. Br Med J 1967; 1:451.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rhee EP, Scott JA, Dighe AS. Case records of the Massachusetts General Hospital. Case 4-2012. A 37-year-old man with muscle pain, weakness, and weight loss. N Engl J Med 2012; 366:553.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shiang JC, Cheng CJ, Tsai MK, et al. Therapeutic analysis in Chinese patients with thyrotoxic periodic paralysis over 6 years. Eur J Endocrinol 2009; 161:911.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li J, Yang XB, Zhao Y. Thyrotoxic periodic paralysis in the Chinese population: clinical features in 45 cases. Exp Clin Endocrinol Diabetes 2010; 118:22.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wong P. Hypokalemic thyrotoxic periodic paralysis: a case series. CJEM 2003; 5:353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schalin-Jantti C, Laine T, Valli-Jaakola K, et al. Manifestation, management and molecular analysis of candidate genes in two rare cases of thyrotoxic hypokalemic periodic paralysis. Horm Res 2005; 63:139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wong GW, Leung TF, Lo AF, et al. Thyrotoxic periodic paralysis in a 14-year-old boy. Eur J Pediatr 2000; 159:934.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan A, Shinde R, Chow CC, et al. In vivo and in vitro sodium pump activity in subjects with thyrotoxic periodic paralysis. BMJ 1991; 303:1096.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin SH, Lin YF. Propranolol rapidly reverses paralysis, hypokalemia, and hypophosphatemia in thyrotoxic periodic paralysis. Am J Kidney Dis 2001; 37:620.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soonthornpun S, Setasuban W, Thamprasit A. Insulin resistance in subjects with a history of thyrotoxic periodic paralysis (TPP). Clin Endocrinol (Oxf) 2009; 70:794.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan A, Shinde R, Chow CC, et al. Hyperinsulinaemia and Na+, K(+)-ATPase activity in thyrotoxic periodic paralysis. Clin Endocrinol (Oxf) 1994; 41:213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fontaine B, Lapie P, Plassart E, et al. Periodic paralysis and voltage-gated ion channels. Kidney Int 1996; 49:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vendrame F, Verrienti A, Parlapiano C, et al. Thyrotoxic periodic paralysis in an Italian man: clinical manifestation and genetic analysis. Ann Clin Biochem 2008; 45:218.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dias Da Silva MR, Cerutti JM, Arnaldi LA, Maciel RM. A mutation in the KCNE3 potassium channel gene is associated with susceptibility to thyrotoxic hypokalemic periodic paralysis. J Clin Endocrinol Metab 2002; 87:4881.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arimura K, Arimura Y, Ng AR, et al. Muscle membrane excitability after exercise in thyrotoxic periodic paralysis and thyrotoxicosis without periodic paralysis. Muscle Nerve 2007; 36:784.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin SH, Huang CL. Mechanism of thyrotoxic periodic paralysis. J Am Soc Nephrol 2012; 23:985.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ryan DP, da Silva MR, Soong TW, et al. Mutations in potassium channel Kir2.6 cause susceptibility to thyrotoxic hypokalemic periodic paralysis. Cell 2010; 140:88.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Song IW, Sung CC, Chen CH, et al. Novel susceptibility gene for nonfamilial hypokalemic periodic paralysis. Neurology 2016; 86:1190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhao SX, Liu W, Liang J, et al. Assessment of Molecular Subtypes in Thyrotoxic Periodic Paralysis and Graves Disease Among Chinese Han Adults: A Population-Based Genome-Wide Association Study. JAMA Netw Open 2019; 2:e193348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Melo MCC, de Souza JS, Kizys MML, et al. Novel lincRNA Susceptibility Gene and Its Role in Etiopathogenesis of Thyrotoxic Periodic Paralysis. J Endocr Soc 2017; 1:809.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Noso S, Babaya N, Hiromine Y, et al. Contribution of Asian Haplotype of KCNJ18 to Susceptibility to and Ethnic Differences in Thyrotoxic Periodic Paralysis. J Clin Endocrinol Metab 2019; 104:6338.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jongjaroenprasert W, Chanprasertyotin S, Butadej S, et al. Association of genetic variants in GABRA3 gene and thyrotoxic hypokalaemic periodic paralysis in Thai population. Clin Endocrinol (Oxf) 2008; 68:646.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kurihara K, Maruyama S, Hosoi K, et al. Regulation of Na+,K+-ATPase in submandibular glands of hypophysectomized male mice by steroid and thyroid hormones. J Histochem Cytochem 1996; 44:703.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tran HA, Reeves GE. Hepatitis C infection and thyrotoxic periodic paralysis--a novel use of an old drug. Am J Med Sci 2008; 336:515.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guerra M, Rodriguez del Castillo A, Battaner E, Mas M. Androgens stimulate preoptic area Na+,K+-ATPase activity in male rats. Neurosci Lett 1987; 78:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin SH, Lin YF, Halperin ML. Hypokalaemia and paralysis. QJM 2001; 94:133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel M, Ladak K. Thyrotoxic Periodic Paralysis: A Case Report and Literature Review. Clin Med Res 2021; 19:148.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Venance SL, Cannon SC, Fialho D, et al. The primary periodic paralyses: diagnosis, pathogenesis and treatment. Brain 2006; 129:8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu YC, Tsai WS, Chau T, Lin SH. Acute hypercapnic respiratory failure due to thyrotoxic periodic paralysis. Am J Med Sci 2004; 327:264.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu CZ, Wu YK, Lin JD, Kuo SW. Thyrotoxic periodic paralysis complicated by acute hypercapnic respiratory failure and ventricular tachycardia. Thyroid 2008; 18:1321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tassone H, Moulin A, Henderson SO. The pitfalls of potassium replacement in thyrotoxic periodic paralysis: a case report and review of the literature. J Emerg Med 2004; 26:157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loh KC, Pinheiro L, Ng KS. Thyrotoxic periodic paralysis complicated by near-fatal ventricular arrhythmias. Singapore Med J 2005; 46:88.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yu TS, Tseng CF, Chuang YY, et al. Potassium chloride supplementation alone may not improve hypokalemia in thyrotoxic hypokalemic periodic paralysis. J Emerg Med 2007; 32:263.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hagel S, Elznerova T, Dietrich W, et al. Chest pain and paralysis after pulse prednisolone therapy an unusual case presentation of thyrotoxic periodic paralysis: a case report. Cases J 2009; 2:7501.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wongraoprasert S, Buranasupkajorn P, Sridama V, Snabboon T. Thyrotoxic periodic paralysis induced by pulse methylprednisolone. Intern Med 2007; 46:1431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gubran C, Narain R, Malik L, Saeed SA. A young man presenting with paralysis after vigorous exercise. BMJ Case Rep 2012; 2012.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yeh FC, Chiang WF, Wang CC, Lin SH. Thyrotoxic periodic paralysis triggered by β2-adrenergic bronchodilators. CJEM 2014; 16:247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldberger ZD. Images in cardiovascular medicine. An electrocardiogram triad in thyrotoxic hypokalemic periodic paralysis. Circulation 2007; 115:e179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu CC, Chau T, Chang CJ, Lin SH. An unrecognized cause of paralysis in ED: thyrotoxic normokalemic periodic paralysis. Am J Emerg Med 2003; 21:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cesur M, Bayram F, Temel MA, et al. Thyrotoxic hypokalaemic periodic paralysis in a Turkish population: three new case reports and analysis of the case series. Clin Endocrinol (Oxf) 2008; 68:143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Griggs RC, Bender AN, Tawil R. A puzzling case of periodic paralysis. Muscle Nerve 1996; 19:362.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hsu YJ, Lin YF, Chau T, et al. Electrocardiographic manifestations in patients with thyrotoxic periodic paralysis. Am J Med Sci 2003; 326:128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin SH, Chu P, Cheng CJ, et al. Early diagnosis of thyrotoxic periodic paralysis: spot urine calcium to phosphate ratio. Crit Care Med 2006; 34:2984.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Summachiwakij S, Sachmechi I. Rhabdomyolysis induced by nonstrenuous exercise in a patient with graves' disease. Case Rep Endocrinol 2014; 2014:286450.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lopez S, Henderson SO. Electrocardiogram changes in Thyrotoxic Periodic Paralysis. West J Emerg Med 2012; 13:512.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang HF, Tsai SC, Pan MS, Shiao CC. Complete heart block during potassium therapy in thyrotoxic periodic paralysis. J Emerg Med 2013; 44:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Couillard P, Wijdicks EF. Flaccid quadriplegia due to thyrotoxic myopathy. Neurocrit Care 2014; 20:296.
          </a>
         </li>
         <li class="breakAll">
          Yeo, PPB, Lee, KO, Cheah, JS. Thyrotoxic periodic paralysis: a study of 51 patients. In: Proceedings of the Second Congress of the Association of Southeast Asian Nations (ASEAN) Federation of Endocrine Societies, Nov 30 - Dec 3, Bangkok, Thailand 1983.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lu KC, Hsu YJ, Chiu JS, et al. Effects of potassium supplementation on the recovery of thyrotoxic periodic paralysis. Am J Emerg Med 2004; 22:544.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shayne P, Hart A. Thyrotoxic periodic paralysis terminated with intravenous propranolol. Ann Emerg Med 1994; 24:736.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Birkhahn RH, Gaeta TJ, Melniker L. Thyrotoxic periodic paralysis and intravenous propranolol in the emergency setting. J Emerg Med 2000; 18:199.
          </a>
         </li>
         <li class="breakAll">
          Rose BD, Post TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th, McGraw-Hill, New York 2001. p.836.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jackson CE, Barohn RJ. Improvement of the exercise test after therapy in thyrotoxic periodic paralysis. Muscle Nerve 1992; 15:1069.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang RY, Lang BH, Chan AC, Wong KP. Evaluating the efficacy of primary treatment for graves' disease complicated by thyrotoxic periodic paralysis. Int J Endocrinol 2014; 2014:949068.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yeung RT, Tse TF. Thyrotoxic periodic paralysis. Effect of propranolol. Am J Med 1974; 57:584.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Conway MJ, Seibel JA, Eaton P. Thyrotoxicosis and periodic paralysis: improvement with beta blockade. Ann Intern Med 1974; 81:332.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ptácek L. The familial periodic paralyses and nondystrophic myotonias. Am J Med 1998; 105:58.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5154 Version 9.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24695373" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Thyrotoxic periodic paralysis: clinical challenges.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27041083" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Thyrotoxic Periodic Paralysis: A Concise Review of the Literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24315723" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Thyrotoxic periodic paralysis: diversity in America.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11256524" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Thyrotoxic periodic paralysis in a patient abusing thyroxine for weight reduction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17693226" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Thyrotoxic hypokalemic periodic paralysis: An overlooked pathology in western countries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19641011" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Thyrotoxic periodic paralysis due to excessive L-thyroxine replacement in a Caucasian man.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19002009" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : An unusual cause of thyrotoxic periodic paralysis: triiodothyronine-containing weight reducing agents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10090117" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Clinical and metabolic features of thyrotoxic periodic paralysis in 24 episodes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16608889" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Clinical review: Thyrotoxic periodic paralysis: a diagnostic challenge.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20089526" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Analytic review: thyrotoxic periodic paralysis: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23939916" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : A 10-year analysis of thyrotoxic periodic paralysis in 135 patients: focus on symptomatology and precipitants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1635436" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Thyrotoxic periodic paralysis in the United States. Report of 7 cases and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2818118" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Thyrotoxic periodic paralysis. Report of 10 cases and review of electromyographic findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17504277" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Thyrotoxic, hypokalaemic periodic paralysis: Polynesians, an ethnic group at risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8758050" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Thyrotoxic periodic paralysis in a Chinese population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18410374" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Hypokalemic thyrotoxic periodic paralysis: clinical characteristics and predictors of recurrent paralytic attacks.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13481091" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : The association of periodic paralysis and hyperthyroidism in Japan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6017520" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Periodic paralysis complicating thyrotoxicosis in Chinese.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22316449" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Case records of the Massachusetts General Hospital. Case 4-2012. A 37-year-old man with muscle pain, weakness, and weight loss.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19755408" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Therapeutic analysis in Chinese patients with thyrotoxic periodic paralysis over 6 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20162834" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Thyrotoxic periodic paralysis in the Chinese population: clinical features in 45 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17466146" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Hypokalemic thyrotoxic periodic paralysis: a case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15795511" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Manifestation, management and molecular analysis of candidate genes in two rare cases of thyrotoxic hypokalemic periodic paralysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11131357" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Thyrotoxic periodic paralysis in a 14-year-old boy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1660744" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : In vivo and in vitro sodium pump activity in subjects with thyrotoxic periodic paralysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11228188" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Propranolol rapidly reverses paralysis, hypokalemia, and hypophosphatemia in thyrotoxic periodic paralysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18759868" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Insulin resistance in subjects with a history of thyrotoxic periodic paralysis (TPP).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7923826" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Hyperinsulinaemia and Na+, K(+)-ATPase activity in thyrotoxic periodic paralysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8770943" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Periodic paralysis and voltage-gated ion channels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18325191" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Thyrotoxic periodic paralysis in an Italian man: clinical manifestation and genetic analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12414843" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : A mutation in the KCNE3 potassium channel gene is associated with susceptibility to thyrotoxic hypokalemic periodic paralysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17722048" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Muscle membrane excitability after exercise in thyrotoxic periodic paralysis and thyrotoxicosis without periodic paralysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22460532" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Mechanism of thyrotoxic periodic paralysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20074522" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Mutations in potassium channel Kir2.6 cause susceptibility to thyrotoxic hypokalemic periodic paralysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26935888" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Novel susceptibility gene for nonfamilial hypokalemic periodic paralysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31050781" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Assessment of Molecular Subtypes in Thyrotoxic Periodic Paralysis and Graves Disease Among Chinese Han Adults: A Population-Based Genome-Wide Association Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29264532" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Novel lincRNA Susceptibility Gene and Its Role in Etiopathogenesis of Thyrotoxic Periodic Paralysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31361309" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Contribution of Asian Haplotype of KCNJ18 to Susceptibility to and Ethnic Differences in Thyrotoxic Periodic Paralysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17970773" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Association of genetic variants in GABRA3 gene and thyrotoxic hypokalaemic periodic paralysis in Thai population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8675991" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Regulation of Na+,K+-ATPase in submandibular glands of hypophysectomized male mice by steroid and thyroid hormones.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19092328" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Hepatitis C infection and thyrotoxic periodic paralysis--a novel use of an old drug.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3039424" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Androgens stimulate preoptic area Na+,K+-ATPase activity in male rats.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11259688" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Hypokalaemia and paralysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34531272" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Thyrotoxic Periodic Paralysis: A Case Report and Literature Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16195244" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : The primary periodic paralyses: diagnosis, pathogenesis and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15166747" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Acute hypercapnic respiratory failure due to thyrotoxic periodic paralysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19014279" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Thyrotoxic periodic paralysis complicated by acute hypercapnic respiratory failure and ventricular tachycardia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14980336" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : The pitfalls of potassium replacement in thyrotoxic periodic paralysis: a case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15678291" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Thyrotoxic periodic paralysis complicated by near-fatal ventricular arrhythmias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17394988" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Potassium chloride supplementation alone may not improve hypokalemia in thyrotoxic hypokalemic periodic paralysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19918467" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Chest pain and paralysis after pulse prednisolone therapy an unusual case presentation of thyrotoxic periodic paralysis: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17827844" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Thyrotoxic periodic paralysis induced by pulse methylprednisolone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22927268" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : A young man presenting with paralysis after vigorous exercise.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24852589" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Thyrotoxic periodic paralysis triggered byβ2-adrenergic bronchodilators.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17296862" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Images in cardiovascular medicine. An electrocardiogram triad in thyrotoxic hypokalemic periodic paralysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12563586" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : An unrecognized cause of paralysis in ED: thyrotoxic normokalemic periodic paralysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17897330" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Thyrotoxic hypokalaemic periodic paralysis in a Turkish population: three new case reports and analysis of the case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8606702" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : A puzzling case of periodic paralysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14501227" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Electrocardiographic manifestations in patients with thyrotoxic periodic paralysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16971853" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Early diagnosis of thyrotoxic periodic paralysis: spot urine calcium to phosphate ratio.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24716006" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Rhabdomyolysis induced by nonstrenuous exercise in a patient with graves' disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23359336" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Electrocardiogram changes in Thyrotoxic Periodic Paralysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22221982" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Complete heart block during potassium therapy in thyrotoxic periodic paralysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24366679" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Flaccid quadriplegia due to thyrotoxic myopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24366679" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Flaccid quadriplegia due to thyrotoxic myopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15666258" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Effects of potassium supplementation on the recovery of thyrotoxic periodic paralysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8092604" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Thyrotoxic periodic paralysis terminated with intravenous propranolol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10699522" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Thyrotoxic periodic paralysis and intravenous propranolol in the emergency setting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10699522" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Thyrotoxic periodic paralysis and intravenous propranolol in the emergency setting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1406763" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Improvement of the exercise test after therapy in thyrotoxic periodic paralysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25147568" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Evaluating the efficacy of primary treatment for graves' disease complicated by thyrotoxic periodic paralysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4432863" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Thyrotoxic periodic paralysis. Effect of propranolol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4855209" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Thyrotoxicosis and periodic paralysis: improvement with beta blockade.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9688022" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : The familial periodic paralyses and nondystrophic myotonias.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
